Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.

Salmon M, Luttmann MA, Foley JJ, Buckley PT, Schmidt DB, Burman M, Webb EF, DeHaas CJ, Kotzer CJ, Barrett VJ, Slack RJ, Sarau HM, Palovich MR, Lainé DI, Hay DW, Rumsey WL.

J Pharmacol Exp Ther. 2013 May;345(2):260-70. doi: 10.1124/jpet.112.202051. Epub 2013 Feb 22.

PMID:
23435542
2.

In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator.

Edelson JD, Makhlina M, Silvester KR, Vengurlekar SS, Chen X, Zhang J, Koziol-White CJ, Cooper PR, Hallam TJ, Hay DW, Panettieri RA Jr.

Pulm Pharmacol Ther. 2013 Apr;26(2):229-38. doi: 10.1016/j.pupt.2012.11.001. Epub 2012 Nov 12.

3.

Temporal and spatial patterns of sea lice levels on sea trout in western Scotland in relation to fish farm production cycles.

Middlemas SJ, Raffell JA, Hay DW, Hatton-Ellis M, Armstrong JD.

Biol Lett. 2010 Aug 23;6(4):548-51. doi: 10.1098/rsbl.2009.0872. Epub 2010 Feb 17.

4.

False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy.

Goldman JA, Blanton WP, Hay DW, Wolfe MM.

Clin Gastroenterol Hepatol. 2009 May;7(5):600-2. doi: 10.1016/j.cgh.2009.02.018. Epub 2009 Feb 24.

PMID:
19245850
5.

Polymorphisms in the endothelin-1 (EDN1) are associated with asthma in two populations.

Zhu G, Carlsen K, Carlsen KH, Lenney W, Silverman M, Whyte MK, Hosking L, Helms P, Roses AD, Hay DW, Barnes MR, Anderson WH, Pillai SG.

Genes Immun. 2008 Jan;9(1):23-9. Epub 2007 Oct 25.

PMID:
17960156
6.

The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.

Chiang N, Serhan CN, Dahlén SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C.

Pharmacol Rev. 2006 Sep;58(3):463-87. Review.

PMID:
16968948
7.

Potential pathophysiological role of endothelin-1 in asthma.

Hay DW, Goldie RG.

Drug News Perspect. 1998 Sep;11(7):411-8.

PMID:
15616682
8.

A novel role for tachykinin neurokinin-3 receptors in regulation of human bronchial Ganglia neurons.

Myers AC, Goldie RG, Hay DW.

Am J Respir Crit Care Med. 2005 Feb 1;171(3):212-6. Epub 2004 Oct 11.

PMID:
15477495
9.

International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor.

Brink C, Dahlén SE, Drazen J, Evans JF, Hay DW, Rovati GE, Serhan CN, Shimizu T, Yokomizo T.

Pharmacol Rev. 2004 Mar;56(1):149-57. Review.

PMID:
15001665
10.

Risk of early surgery for Crohn's disease: implications for early treatment strategies.

Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, Bensen S, Bousvaros A, Cave D, Cooley JS, Cooper HL, Edwards ST, Farrell RJ, Griffin MJ, Hay DW, John A, Lidofsky S, Olans LB, Peppercorn MA, Rothstein RI, Roy MA, Saletta MJ, Shah SA, Warner AS, Wolf JL, Vecchio J, Winter HS, Zawacki JK.

Am J Gastroenterol. 2003 Dec;98(12):2712-8.

PMID:
14687822
11.

International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors.

Brink C, Dahlén SE, Drazen J, Evans JF, Hay DW, Nicosia S, Serhan CN, Shimizu T, Yokomizo T.

Pharmacol Rev. 2003 Mar;55(1):195-227. Review.

PMID:
12615958
12.

A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit.

Podolin PL, Bolognese BJ, Foley JJ, Schmidt DB, Buckley PT, Widdowson KL, Jin Q, White JR, Lee JM, Goodman RB, Hagen TR, Kajikawa O, Marshall LA, Hay DW, Sarau HM.

J Immunol. 2002 Dec 1;169(11):6435-44.

13.

Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.

Hay DW, Giardina GA, Griswold DE, Underwood DC, Kotzer CJ, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Martin LD, Kilian D, Legos JJ, Barone FC, Luttmann MA, Grugni M, Raveglia LF, Sarau HM.

J Pharmacol Exp Ther. 2002 Jan;300(1):314-23.

PMID:
11752131
14.

Interleukin-8 receptor antagonists in pulmonary diseases.

Hay DW, Sarau HM.

Curr Opin Pharmacol. 2001 Jun;1(3):242-7. Review.

PMID:
11712746
15.

Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.

Blaney FE, Raveglia LF, Artico M, Cavagnera S, Dartois C, Farina C, Grugni M, Gagliardi S, Luttmann MA, Martinelli M, Nadler GM, Parini C, Petrillo P, Sarau HM, Scheideler MA, Hay DW, Giardina GA.

J Med Chem. 2001 May 24;44(11):1675-89.

PMID:
11356103
16.

Spawning success in Atlantic salmon (Salmo salar L.): a long-term DNA profiling-based study conducted in a natural stream.

Taggart JB, McLaren IS, Hay DW, Webb JH, Youngson AF.

Mol Ecol. 2001 Apr;10(4):1047-60.

PMID:
11348510
17.

Cysteinyl leukotriene receptor assays.

Muccitelli RM, Luttmann MA, Hay DW.

Curr Protoc Pharmacol. 2001 May;Chapter 4:Unit 4.16. doi: 10.1002/0471141755.ph0416s09.

PMID:
22293965
18.

Differential modulation of endothelin ligand-induced contraction in isolated tracheae from endothelin B (ET(B)) receptor knockout mice.

Hay DW, Douglas SA, Ao Z, Moesker RM, Self GJ, Rigby PJ, Luttmann MA, Goldie RG.

Br J Pharmacol. 2001 Apr;132(8):1905-15.

19.

Variation in river water temperatures in an upland stream over a 30-year period.

Langan SJ, Johnston L, Donaghy MJ, Youngson AF, Hay DW, Soulsby C.

Sci Total Environ. 2001 Jan 29;265(1-3):195-207.

PMID:
11227266
20.

Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor.

Sarau HM, Feild JA, Ames RS, Foley JJ, Nuthulaganti P, Schmidt DB, Buckley PT, Elshourbagy NA, Brawner ME, Luttmann MA, Giardina GA, Hay DW.

Eur J Pharmacol. 2001 Feb 16;413(2-3):143-50.

PMID:
11226387
21.

Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate.

Ammit AJ, Hoffman RK, Amrani Y, Lazaar AL, Hay DW, Torphy TJ, Penn RB, Panettieri RA Jr.

Am J Respir Cell Mol Biol. 2000 Dec;23(6):794-802.

PMID:
11104733
22.

Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in mice.

Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z, Luttmann MA, Pullen M, Nambi P, Hay DW, Ohlstein EH.

J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S78-81.

PMID:
11078342
23.

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE.

Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L895-902.

24.

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, Martin LD, Legos JJ, Whitmore RG, Barone FC, Medhurst AD, Luttmann MA, Giardina GA, Hay DW.

J Pharmacol Exp Ther. 2000 Oct;295(1):373-81.

PMID:
10992004
25.

Human urotensin-II is a potent spasmogen of primate airway smooth muscle.

Hay DW, Luttmann MA, Douglas SA.

Br J Pharmacol. 2000 Sep;131(1):10-2.

26.

Chronic obstructive pulmonary disease: emerging therapies.

Hay DW.

Curr Opin Chem Biol. 2000 Aug;4(4):412-9. Review.

PMID:
10959769
27.

Evidence that the proposed novel human "neurokinin-4" receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin.

Sarau HM, Mooney JL, Schmidt DB, Foley JJ, Buckley PT, Giardina GA, Wang DY, Lee JA, Hay DW.

Mol Pharmacol. 2000 Sep;58(3):552-9.

PMID:
10953048
28.

Differences in time-related cardiopulmonary responses to hypoxia in three rat strains.

Bochnowicz S, Osborn RR, Luttmann MA, Louden C, Hart T, Hay DW, Underwood DC.

Clin Exp Hypertens. 2000 Jul;22(5):471-92.

PMID:
10937839
29.

Role of neurokinin receptors in the behavioral effect of intravesical antigen infusion in guinea pig bladder.

Ruggieri MR, Filer-Maerten S, Hieble JP, Hay DW.

J Urol. 2000 Jul;164(1):197-202.

PMID:
10840459
30.

SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.

Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE.

J Pharmacol Exp Ther. 2000 Apr;293(1):281-8.

PMID:
10734180
31.

The antitussive activity of delta-opioid receptor stimulation in guinea pigs.

Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC.

J Pharmacol Exp Ther. 2000 Feb;292(2):803-9.

PMID:
10640321
32.

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA.

Nature. 1999 Sep 16;401(6750):282-6. Erratum in: Nature 1999 Dec 23-30;402(6764):898.

PMID:
10499587
33.

Endothelin receptors and calcium translocation pathways in human airways.

Hay DW, Luttmann MA, Muccitelli RM, Goldie RG.

Naunyn Schmiedebergs Arch Pharmacol. 1999 May;359(5):404-10.

PMID:
10498291
34.

Endothelin B receptor modulates inflammatory pain and cutaneous inflammation.

Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z, Luttmann MA, Pullen M, Nambi P, Hay DW, Ohlstein EH.

Mol Pharmacol. 1999 Oct;56(4):807-12.

PMID:
10496965
35.

In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.

Sarau HM, Foley JJ, Schmidt DB, Martin LD, Webb EF, Tzimas MN, Breton JJ, Chabot-Fletcher M, Underwood DC, Hay DW, Kingsbury WD, Chambers PA, Pendrak I, Jakas DR, Sathe GM, Van Horn S, Daines RA, Griswold DE.

Prostaglandins Leukot Essent Fatty Acids. 1999 Jul;61(1):55-64.

PMID:
10477044
36.

Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.

Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, Schmidt DB, Muccitelli RM, Jenkins O, Murdock PR, Herrity NC, Halsey W, Sathe G, Muir AI, Nuthulaganti P, Dytko GM, Buckley PT, Wilson S, Bergsma DJ, Hay DW.

Mol Pharmacol. 1999 Sep;56(3):657-63.

PMID:
10462554
37.

Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats.

Salmon M, Walsh DA, Huang TJ, Barnes PJ, Leonard TB, Hay DW, Chung KF.

Br J Pharmacol. 1999 Jul;127(5):1151-8.

38.

Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists.

Giardina GA, Artico M, Cavagnera S, Cerri A, Consolandi E, Gagliardi S, Graziani D, Grugni M, Hay DW, Luttmann MA, Mena R, Raveglia LF, Rigolio R, Sarau HM, Schmidt DB, Zanoni G, Farina C.

Farmaco. 1999 Jun 30;54(6):364-74.

PMID:
10443017
39.

Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat.

Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Louden CS, Hart TK, Elliott JD, Hay DW.

Pulm Pharmacol Ther. 1999;12(1):13-26.

PMID:
10208832
40.

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).

Giardina GA, Raveglia LF, Grugni M, Sarau HM, Farina C, Medhurst AD, Graziani D, Schmidt DB, Rigolio R, Luttmann M, Cavagnera S, Foley JJ, Vecchietti V, Hay DW.

J Med Chem. 1999 Mar 25;42(6):1053-65.

PMID:
10090788
41.

Putative mediator role of endothelin-1 in asthma and other lung diseases.

Hay DW.

Clin Exp Pharmacol Physiol. 1999 Feb;26(2):168-71. Review.

PMID:
10065341
42.

Preface

Battistini B, Goldie RG, Hay DWP.

Pulm Pharmacol Ther. 1998 Apr;11(2-3):77-8. No abstract available.

PMID:
9918739
43.

Endothelin-1: an interesting peptide or an important mediator in pulmonary diseases?

Hay DW.

Pulm Pharmacol Ther. 1998 Apr-Jun;11(2-3):141-6. Review. No abstract available.

PMID:
9918746
44.

Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.

Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttmann MA, Hay DW, Gorycki PD, Christensen SB, Torphy TJ.

J Pharmacol Exp Ther. 1998 Dec;287(3):988-95.

PMID:
9864284
45.

Food restriction-mediated adrenal influences on antigen-induced bronchoconstriction and airway eosinophil influx in the guinea pig.

Underwood DC, Matthews JK, Osborn RR, Hay DW.

Int Arch Allergy Immunol. 1998 Sep;117(1):52-9.

PMID:
9751848
46.
47.

Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.

Ohlstein EH, Nambi P, Hay DW, Gellai M, Brooks DP, Luengo J, Xiang JN, Elliott JD.

J Pharmacol Exp Ther. 1998 Aug;286(2):650-6.

PMID:
9694916
48.

Chronic hypoxia-induced cardiopulmonary changes in three rat strains: inhibition by the endothelin receptor antagonist SB 217242.

Underwood DC, Bochnowicz S, Osborn RR, Louden CS, Hart TK, Ohlstein EH, Hay DW.

J Cardiovasc Pharmacol. 1998;31 Suppl 1:S453-5.

PMID:
9595510
49.

Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype?

Hay DW, Luttmann MA, Pullen MA, Nambi P.

J Pharmacol Exp Ther. 1998 Feb;284(2):669-77.

PMID:
9454813
50.

Supplemental Content

Support Center